| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical Investigation |
1 Imaging Science Laboratories, Mount Sinai School of Medicine, New York, New York; 2 Cardiovascular Imaging Clinical Trials Unit, Mount Sinai School of Medicine, New York, New York; 3 Division of Nuclear Medicine, Department of Radiology, Mount Sinai School of Medicine, New York, New York; 4 Mount Sinai School of Medicine, New York, New York, and Merck Research Laboratories, Rahway, New Jersey; and 5 The Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Cardiovascular Health Center, Mount Sinai School of Medicine, New York, New York
Correspondence: For correspondence or reprints contact either of the following: James Rudd, ACCI, Box 110, Addenbrokes Hospital, Cambridge CB2 2QQ, U.K. E-mail: jhfr2{at}cam.ac.uk Zahi A. Fayad, ISL, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1030, New York, NY 10029. E-mail: zahi.fayad{at}mssm.edu
Atherosclerosis imaging with 18F-FDG PET is useful for tracking inflammation within plaque and monitoring the response to drug therapy. Short-term reproducibility of this technique in peripheral artery disease has not been assessed, and the optimal method of 18F-FDG quantification is still debated. We imaged 20 patients with vascular disease using 18F-FDG PET twice, 14 d apart, and used these data to assess reproducibility measures and compare 2 methods of 18F-FDG uptake measurement. We also reviewed the literature on quantification methods to determine the optimal measures of arterial 18F-FDG uptake for future studies. Methods: Twenty patients with vascular disease underwent PET/CT of the iliac, femoral, and carotid arteries 90 min after 18F-FDG administration. In 19 patients, repeat testing was performed at 2 wk. Coregistration and attenuation correction were performed with CT. Vessel 18F-FDG uptake was measured as both the mean and maximum blood-normalized standardized uptake value (SUV), known as the target-to-background ratio (TBR). We assessed interscan, interobserver, and intraobserver agreement. Results: Nineteen patients completed both imaging sessions. The carotid and peripheral arteries all have excellent short-term reproducibility of the 18F-FDG signal, with intraclass correlation coefficients all greater than 0.8 for all measures of reproducibility. Both mean and maximum TBR measurements for quantifying 18F-FDG uptake are equally reproducible. 18F-FDG uptake was significantly higher in the carotid arteries than in both iliac and femoral vessels (P < 0.001 for both). Conclusion: We found that both mean and maximum TBR in the carotid, iliac, and femoral arteries were highly reproducible. We suggest the mean TBR be used for tracking systemic arterial therapies, whereas the maximum TBR is optimal for detecting and monitoring local, plaque-based therapy.
Key Words: atherosclerosis • positron emission tomography • 18F-FDG • inflammation • methodology
* Contributed equally to this work.
COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  A. Rominger, T. Saam, E. Vogl, C. Ubleis, C. la Fougere, S. Forster, A. Haug, P. Cumming, M. F. Reiser, K. Nikolaou, et al. In Vivo Imaging of Macrophage Activity in the Coronary Arteries Using 68Ga-DOTATATE PET/CT: Correlation with Coronary Calcium Burden and Risk Factors J. Nucl. Med., February 1, 2010; 51(2): 193 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, D. Abendschein, G. E. Woodard, R. Rossin, K. McCommis, J. Zheng, M. J. Welch, and P. K. Woodard Molecular Imaging of Atherosclerotic Plaque with 64Cu-Labeled Natriuretic Peptide and PET J. Nucl. Med., January 1, 2010; 51(1): 85 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Libby, P. M. Ridker, G. K. Hansson, and for the Leducq Transatlantic Network on Atherothro Inflammation in Atherosclerosis From Pathophysiology to Practice. J. Am. Coll. Cardiol., December 1, 2009; 54(23): 2129 - 2138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Prado, E. J. Fine, W. Koba, D. Zhao, M. A. Rossi, H. B. Tanowitz, and L. A. Jelicks Micro-Positron Emission Tomography in the Evaluation of Trypanosoma cruzi-Induced Heart Disease: Comparison with Other Modalities Am J Trop Med Hyg, November 1, 2009; 81(5): 900 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Matter, M. Stuber, and M. Nahrendorf Imaging of the unstable plaque: how far have we got? Eur. Heart J., November 1, 2009; 30(21): 2566 - 2574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nahrendorf, E. Keliher, P. Panizzi, H. Zhang, S. Hembrador, J.-L. Figueiredo, E. Aikawa, K. Kelly, P. Libby, and R. Weissleder 18F-4V for PET-CT Imaging of VCAM-1 Expression in Atherosclerosis J. Am. Coll. Cardiol. Img., October 1, 2009; 2(10): 1213 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rominger, T. Saam, S. Wolpers, C. C. Cyran, M. Schmidt, S. Foerster, K. Nikolaou, M. F. Reiser, P. Bartenstein, and M. Hacker 18F-FDG PET/CT Identifies Patients at Risk for Future Vascular Events in an Otherwise Asymptomatic Cohort with Neoplastic Disease J. Nucl. Med., October 1, 2009; 50(10): 1611 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nahrendorf, P. Waterman, G. Thurber, K. Groves, M. Rajopadhye, P. Panizzi, B. Marinelli, E. Aikawa, M. J. Pittet, F. K. Swirski, et al. Hybrid In Vivo FMT-CT Imaging of Protease Activity in Atherosclerosis With Customized Nanosensors Arterioscler Thromb Vasc Biol, October 1, 2009; 29(10): 1444 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H.F. Rudd, M. Elkhawad, and Z. A. Fayad Vascular Imaging with 18F-FDG PET/CT: Optimal 18F-FDG Circulation Time? J. Nucl. Med., September 1, 2009; 50(9): 1560 - 1560. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Saraste, S. G. Nekolla, and M. Schwaiger Cardiovascular molecular imaging: an overview Cardiovasc Res, September 1, 2009; 83(4): 643 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Laitinen, A. Saraste, E. Weidl, T. Poethko, A. W. Weber, S. G. Nekolla, P. Leppanen, S. Yla-Herttuala, G. Holzlwimmer, A. Walch, et al. Evaluation of {alpha}v{beta}3 Integrin-Targeted Positron Emission Tomography Tracer 18F-Galacto-RGD for Imaging of Vascular Inflammation in Atherosclerotic Mice Circ Cardiovasc Imaging, July 1, 2009; 2(4): 331 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H.F. Rudd, F. Hyafil, and Z. A. Fayad Inflammation Imaging in Atherosclerosis Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 1009 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Menezes, C. W. Kotze, B. F. Hutton, R. Endozo, J. C. Dickson, I. Cullum, S. W. Yusuf, P. J. Ell, and A. M. Groves Vascular Inflammation Imaging with 18F-FDG PET/CT: When to Image? J. Nucl. Med., June 1, 2009; 50(6): 854 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sanz, P. R. Moreno, and V. Fuster The Year in Atherothrombosis J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1326 - 1337. [Full Text] [PDF]
|
|
|
|
|
|
J. H.F. Rudd, K. S. Myers, S. Bansilal, J. Machac, M. Woodward, V. Fuster, M. E. Farkouh, and Z. A. Fayad Relationships Among Regional Arterial Inflammation, Calcification, Risk Factors, and Biomarkers: A Prospective Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Imaging Study Circ Cardiovasc Imaging, March 1, 2009; 2(2): 107 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Osborn and F. A. Jaffer The year in molecular imaging. J. Am. Coll. Cardiol. Img., January 1, 2009; 2(1): 97 - 113. [Full Text] [PDF]
|
|
|
|
|
|
M. Nahrendorf, D. E. Sosnovik, B. A. French, F. K. Swirski, F. Bengel, M. M. Sadeghi, J. R. Lindner, J. C. Wu, D. L. Kraitchman, Z. A. Fayad, et al. Multimodality Cardiovascular Molecular Imaging, Part II Circ Cardiovasc Imaging, January 1, 2009; 2(1): 56 - 70. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
